Methylphenidate (MPH) is widely prescribed for adults with attention deficit hyperactivity
disorder (ADHD), but data on long-term treatment and maintenance of effect are lacking …

Aim The aim of this study was to assess the impact of switching from immediate-release (IR)
methylphenidate (MPH) to OROS® MPH (CONCERTA®), a once-daily long-acting MPH …

Objective: To evaluate the long-term effects of methylphenidate imediate-release (MPH-IR),
and to confirm the efficacy established in previous meta-analyses of short-term studies …

OBJECTIVE: Few studies have assessed effectiveness and tolerability of stimulants when
used for prolonged periods in children with attention-deficit/hyperactivity disorder (ADHD) …

Objective: The aim of this study was to compare the pharmacodynamics of a new multilayer-
release (MLR) formulation methylphenidate (MPH; Biphentin®) with immediate-release (IR) …

Objectives: To evaluate the efficacy and safety of once-daily serdexmethylphenidate/
dexmethylphenidate (SDX/d-MPH) capsules (Azstarys™) compared with placebo in children …

Objective: Evening-dosed HLD200 is a delayed-release and extended-release
methylphenidate (DR/ER-MPH) formulation consisting of uniform, dual-layered microbeads …

This open study explored whether methylphenidate could be tolerated and effective in
improving the quality of life (QOL) and attention deficit hyperactivity disorder (ADHD) …

Objective: The purpose of this study was to examine the behavioral effects of four doses of
psychostimulant medication, combining extended-release methylphenidate (MPH) in the …

Objective: Studies of vital signs in children and adolescents with attention-
deficit/hyperactivity disorder (ADHD) receiving stimulants indicate a variable effect on blood …